市場調查報告書
商品編碼
1276313
全球腸道疾病檢測市場規模,份額,行業趨勢分析報告:按最終用戶,按疾病類型,按產品類型(試劑/耗材,設備),按檢測方法,地區,展望/預測,2023-2029年Global Enteric Disease Testing Market Size, Share & Industry Trends Analysis Report By End User, By Disease Type, By Product Type (Reagents & Consumables and Equipment), By Technique, By Regional Outlook and Forecast, 2023 - 2029 |
在預測期內,腸道疾病檢測市場規模預計將以 3.2% 的複合年增長率增長,到 2029 年將達到 46 億美元。
腸道疾病是由影響腸道的細菌、病毒和寄生生物引起的。 這些疾病中有許多可以在人與人之間傳播,通常是由食用受污染的食物或飲料引起的。 腸道感染的症狀包括噁心、腹痛、發冷、發燒、腹瀉和食慾不振。
已發現腸道細菌是許多水源性疾病和食源性疾病的主要原因。 腹瀉和溶血性尿毒症綜合徵 (HUS) 在世界範圍內變得越來越普遍。 腸道細菌感染是最常見的原因。 由於腹瀉發病率上升、新興國家發病率上升、政府意識提高以及政府和公共機構的各種舉措等因素,預計在整個預測期內,腸道細菌性疾病檢測市場將擴大。
COVID-19 影響分析
由於大流行影響了醫療保健優先事項,因此 COVID-19 檢測和治療優先於腸道疾病檢測。 COVID-19 大流行需要大量資源重新分配給 COVID-19 檢測、治療和疫苗接種工作。 因此,資源已從其他醫療保健領域轉移,例如腸道疾病檢測。 這是由多種因素共同造成的,包括醫療保健能力下降和社會疏遠做法。 COVID-19 疫情擾亂了許多關於腸道疾病的研究項目,並將資源轉移到 COVID-19 研究上。 大流行期間對腸道疾病檢測試劑盒的需求減少對市場增長產生了負面影響。
市場增長因素
全球腸道疾病患病率不斷上升
這些檢測也證明了艱難梭菌、志賀氏菌、大腸桿菌、霍亂和沙門氏菌病等腸道疾病的流行率不斷上升,這些疾病可導致嚴重腹瀉甚至死亡。 腸道感染每年影響全球數百萬人,尤其是在衛生條件差的欠發達國家。 因此,預計腸道疾病患病率上升將在整個預測期內推動市場增長。
通過積極的研發增加技術突破
腸病檢測的需求可能受益於腸病檢測設備和檢測方法的技術發展和改進。 改進的測試效率、具有成本效益的測試和更快的測試結果有助於產品開發。 此外,醫療保健企業越來越多地連接到更高效、更有效且價格更實惠的計算硬件,這些硬件具有增強的網絡連接、改進的軟件和先進的傳感器。 因此,未來幾年市場可能會從這些變量中獲益。
市場製約因素
測試和採樣成本高
由於具有先進的功能和特點,自動腸道疾病檢測儀器的價格高於手動檢測儀器。 當您將介質、設備和人工成本考慮在內時,對於某些最終用戶來說,這似乎貴得令人望而卻步。 此外,在實驗室中部署大量系統會顯著增加總資本成本投資。 分子診斷技術的利用,尤其是與單重檢測相比的多重檢測,是醫療保健行業的最新發展。 然而,多重檢測設備的成本相對較高,安裝設備所需的初始投資也很高。 在成本效益高的替代品出現之前,這一因素將阻礙市場增長。
產品類型展望
按產品類型劃分,腸道疾病檢測市場分為試劑/耗材和儀器。 2022年腸道疾病檢測市場,器械板塊實現大幅增長。 在此過程中使用了不同類型的腸道疾病測試,推動了這一細分市場的增長。 自動分析儀用於對腸道疾病進行快速檢測。 這些測試可以檢測樣品中病原體的特定抗原或遺傳物質的存在。
檢驗方法展望
腸道疾病檢測市場按檢測方法分為分子診斷和免疫診斷。 免疫診斷部門將在 2022 年佔據腸道疾病檢測市場最大的收入份額。 免疫診斷測試可在短短幾個小時內得出結果,使腸道疾病的早期診斷和治療成為可能。 免疫診斷測試甚至可以檢測到少量的病原體和抗體,使其成為高度敏感和特異的測試。 這意味著您可以查明特定病原體的存在並排除導致患者症狀的其他可能性。
按疾病類型劃分的前景
腸道疾病檢測市場按疾病類型分為三類:細菌、病毒和寄生蟲。 沙門氏菌病、霍亂、大腸桿菌和幽門螺桿菌等細菌性腸病的高流行以及用於診斷的腸道疾病檢測產品的廣泛使用正在推動這一細分市場的增長。 由於對細菌性腸病診斷知識的提高和全球細菌性腸病發病率的上升,預計該類別也將經歷快速增長。
最終用戶視角
按最終用戶劃分,腸道疾病檢測市場分為學術和研究機構、醫院實驗室以及製藥和生物技術公司。 2022 年,學術和研究機構部門在腸道疾病檢測市場中佔據了相當大的收入份額。 學術和研究機構在腸道疾病的公共衛生監測中發揮著重要作用。 對人群中的腸道疾病進行檢測和監測有助於確定疫情、制定應對計劃以及實施預防和控制策略。 研究實驗室在識別引起腸道疾病的新病原體方面發揮著重要作用。
區域展望
按地區劃分,對北美、歐洲、亞太地區和拉美地區的腸道疾病檢測市場進行了分析。 2022 年,北美市場在腸道疾病檢測市場的收入份額最大。 該地區許多重要參與者的存在,以及腸道疾病檢測產品製造技術的改進,正在推動市場的擴張。 這主要是由於腸道疾病患者增加,政府加大對腸道疾病診斷研究的支持力度,以及發達國家資本收入的顯著增加。
市場進入者採取的主要策略是收購。 根據基數矩陣中的分析,Thermo Fisher Scientific, Inc. 是腸道疾病檢測市場的先行者。 Neogen Corporation、Bureau Veritas S.A. 和 Eurofins Scientific SE 等公司是腸道疾病檢測市場的領先創新者。
The Global Enteric Disease Testing Market size is expected to reach $4.6 billion by 2029, rising at a market growth of 3.2% CAGR during the forecast period.
Infections of the gastrointestinal tract, encompassing the small intestine, large intestine, and stomach, are known as enteric diseases. Bacteria, viruses, and parasites are just a few of the microorganisms that might cause these diseases. Salmonellosis, shigellosis, norovirus, rotavirus, amebiasis, cryptosporidiosis, and giardiasis are typical examples of enteric diseases. Others include cholera, Clostridium difficile (C. difficile), Escherichia coli (E. coli), shigellosis, and Helicobacter pylori (H. pylori).
To determine the exact pathogen triggering an enteric disease and to diagnose enteric diseases, numerous laboratory tests are employed. These tests often entail checking samples of blood, feces, or other fluids from the body for the presence of viruses, bacteria, and parasites known as enteric pathogens.
Enteric disorders are caused by bacterial, viral, and parasitic microorganisms that affect the intestines. Many of these illnesses can be spread from person to person and are typically brought on by consuming tainted food or drink. The symptoms of enteric infections include nausea, stomach pain, chills, fever, diarrhea, and loss of appetite.
One of the primary agents behind many water- and food-borne illnesses has been shown to be enteric bacteria. Diarrhea and hemolytic uremic syndrome (HUS) are becoming more common worldwide. Enteric bacterial infections are the most frequent cause. The enteric disease testing market is expected to expand throughout the forecast period due to factors such as rising rates of diarrhea, rising rates in emerging nations, higher government awareness, and various government and public sector initiatives.
COVID-19 Impact Analysis
COVID-19 testing and treatment took precedence over enteric illness testing as a result of the pandemic's impact on healthcare priorities. The COVID-19 pandemic required a massive redirection of resources towards COVID-19 testing, treatment, and vaccination efforts. This led to a diversion of resources away from other areas of healthcare, including enteric disease testing. This was due to a combination of factors, including reduced healthcare capacity, and social distancing measures. The COVID-19 pandemic disrupted many research projects related to enteric diseases, with resources and personnel being diverted towards COVID-19 research. The demand for enteric disease testing kits decreased during the pandemic, which negatively impacted market growth.
Market Growth Factors
Increasing prevalence of enteric disease worldwide
The rise in the prevalence of several other enteric diseases such as clostridium difficile (C. difficile), shigellosis, Escherichia coli (E. coli), cholera, and salmonellosis-all of which can result in severe diarrhea or even death-also contributes to the increasing demand for these tests. Rising Millions of people contract enteric infections every year worldwide, but they are particularly prevalent in underdeveloped nations with subpar sanitation. Hence, the rising prevalence of enteric disease will propel the growth of the market throughout the forecast period.
Rising number of technological breakthroughs owing to increased R&D
The demand for enteric disease testing may benefit from the growing technological developments and improvements in enteric disease testing equipment and methods. Testing efficiency gains, cost-effective testing, and quick test results may contribute to product development. Additionally, the healthcare business is embracing the growing trend of more efficient, effective, and affordable computing hardware connected to greater network connectivity, improved software, and advanced sensors. In light of this, the market may benefit financially from these variables in the years to come.
Market Restraining Factors
High cost of testing and sampling
Automated enteric disease testing instruments are priced higher than their manual counterparts due to their advanced features and functions. The calculated cost of the media, instrument, and labor may be perceived as prohibitively expensive by certain end users. In addition, implementing numerous systems in testing laboratories has significantly increased the total capital cost investment. Utilizing molecular diagnostic techniques, particularly multiplexed assays, is a recent development in the healthcare industry compared to singleplex assays. However, the cost of multiplexed assay equipment is comparatively high, and the initial investment required for instrument installation is higher. This factor will impede the market's growth until cost-effective alternatives become available.
Product Type Outlook
Based on product type, the enteric disease testing market is characterized into reagents & consumables and equipment. The equipment segment procured a considerable growth rate in the enteric disease testing market in 2022. Different types of enteric disease testing are used in the process, which is propelling the growth of the segment. Automated analyzers are used to perform rapid tests for enteric diseases. These tests can detect the presence of specific antigens or genetic material from the pathogen in a sample.
Technique Outlook
On the basis of technique, the enteric disease testing market is classified into molecular diagnostics and immunodiagnostics. The immunodiagnostics segment acquired the largest revenue share in the enteric disease testing market in 2022. Immunodiagnostic tests can provide results quickly, sometimes in as little as a few hours, which allows for earlier diagnosis and treatment of enteric diseases. Immunodiagnostic tests can detect even small amounts of pathogens or antibodies, making them highly sensitive and specific. This means they can accurately identify the presence of a specific pathogen and rule out other potential causes of the patient's symptoms.
Disease Type Outlook
By disease type, the enteric disease testing market is divided into bacterial, viral, and parasitic. The high prevalence of bacterial enteric diseases such as salmonellosis, cholera, E. coli, and Helicobacter pylori, as well as the widespread utilization of enteric disease testing products for the diagnosis, are driving the growth of this market segment. In addition, due to increased knowledge of bacterial enteric disease diagnosis and a rising incidence of bacterial enteric diseases globally, the category is anticipated to experience rapid growth.
End User Outlook
Based on end user, the enteric disease testing market is segmented into academic & research institutes, hospital laboratories, and pharmaceutical & biotechnology companies. The academic & research institutes segment acquired a substantial revenue share in the enteric disease testing market in 2022. Academic and research institutes play a vital role in public health surveillance for enteric diseases. Testing and monitoring of enteric diseases in populations can help in identifying outbreaks, developing response plans, and implementing prevention and control strategies. Research institutes play a crucial role in identifying new pathogens responsible for enteric diseases.
Regional Outlook
Region wise, the enteric disease testing market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America segment recorded the largest revenue share in the enteric disease testing market in 2022. The presence of a number of significant players as well as improvements in the manufacturing technology of enteric disease testing products in the region is what is driving the market's expansion. This is mostly due to an increase in the number of patients with enteric diseases, increased government support for research into the diagnosis of enteric diseases, and a sizable increase in capital income in industrialized nations.
The major strategies followed by the market participants are Acquisitions. Based on the Analysis presented in the Cardinal matrix; Thermo Fisher Scientific, Inc. is the forerunner in the Enteric Disease Testing Market. Companies such as Neogen Corporation, Bureau Veritas S.A., and Eurofins Scientific SE are some of the key innovators in Enteric Disease Testing Market.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck KGaA, Thermo Fisher Scientific, Inc., SGS S.A., Eurofins Scientific SE, Bureau Veritas S.A., Intertek Group PLC, TUV Nord Group, PerkinElmer, Inc., Becton, Dickinson and Company and Neogen Corporation.
Recent Strategies Deployed in Enteric Disease Testing Market
Mergers and Acquisitions:
Jan-2023: Thermo Fisher Scientific Inc. took over The Binding Site Group, a global leader in specialty diagnostics. Through this acquisition, Thermo Fisher Scientific Inc. would be able to extend its current specialty diagnostics portfolio along with pioneering innovation in monitoring and diagnostics for numerous myelomas.
Sep-2022: Bureau Veritas took over Galbraith Laboratories, a US-based operator of contract analytical testing. The addition of Galbraith expands the acquiring company's market presence in the personal care, industrial, and consumer healthcare markets, and further expands Bureau Veritas' market position in the North American region.
Sep-2022: Neogen announced the completion of a merger with 3M's Food Safety business. 3M's food safety business is merged with Neogen. The combination expands the merged company's geographical footprint, digitization capabilities, etc.
Jul-2022: Neogen completed the acquisition of Thai-Neo Biotech, a Thailand-based distributor of food safety products. The acquisition enables the acquiring company to establish a direct presence in Thailand and the Southeast Asian region. Further, the addition of Thai-Neo Biotech perfectly complements Neogen's operations in China, Australia, and India.
Jun-2022: Eurofins acquired a majority stake in Ajal for Laboratories, a Saudi Arabia-based provider of laboratory services. This acquisition broadens the acquiring company's food and pharmaceutical product test offerings in Saudi Arabia. Further, the acquisition reflects Eurofins' commitment to developing a local and regional laboratory network across the whole Middle East.
Sep-2021: Neogen acquired CAPInnoVet, a US-based provider of animal health medicines and products. This acquisition provides Neogen entry to the retail parasiticide market. The acquired company will be a part of Neogen's Animal Safety business segment.
Apr-2021: Thermo Fisher Scientific Inc. took over PPD, Inc., a pharmaceutical company engaged in clinical research. Through this acquisition, the company would provide a vast range of services in the clinical development spectrum. This includes the development and manufacturing of the drug product, healthcare outcomes, trial logistics., scientific discovery, etc.
Partnerships, Collaborations and Agreements:
Oct-2022: Thermo Fisher Scientific came into partnership with Genoox, a provider of fast and accurate tools to solve complex, genomic data challenges, delivering advanced, and end-to-end genomic analysis tools. The partnership aims to automate the interpretation and reporting of cytogenetic research data with AI. ChAS users can access Franklin, Genoox's cloud-based AI platform with the launch of CytoScan Automated Interpretation and Reporting (AIR) solution for making cytogenetic research data analysis easy.
Apr-2022: SGS came into partnership with Liveome, a South Korea-based operator of microbiome research-based firm. The partnership focuses on the development and commercialization of LIV001, an inflammatory bowel disease (IBD) candidate. The partnership demonstrates SGS' ability to provide its services globally.
Product Launches and Expansions:
Dec-2022: Thermo Fisher introduced TrueMark Infectious Disease Research Panels, developed to enable quick and precise detection and categorization for investigating microorganisms. The new panel are real-time polymerase chain reaction (PCR) syndromic panels and gives an option to the user to choose between standard or custom panels.
Oct-2022: Thermo Fisher launched TaqPath Enteric Bacterial Select Panel, a CE-IVD marked test intended for common Gastrointestinal bacteria. The new test detects gastrointestinal (GI) bacteria and speeds up the root cause identification process. The GI bacteria detecting test is based on polymerase chain reaction (PCR) technology to examine the stool samples. The test can deliver results with 98% specificity, and sensitivity within two hours.
Market Segments covered in the Report:
By End User
By Disease Type
By Product Type
By Technique
By Geography
Companies Profiled
Unique Offerings from KBV Research
List of Figures